TrialLeukemia & lymphoma2025

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.

Charalambos Andreadis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.